The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...

Genentech, part of Roche Group (USOTC:RHHBY), has received FDA approval for Tecentriq in combination with chemotherapy for a ...

FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, ...

Authorisation positions monoclonal antibody as a new post-surgery standard of care in stage III deficient mismatch repair ...

The Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy on Oct. 8 as an ...

The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy. Roche has added a twelfth US indication to Tecentriq (atezolizumab). The ...

The new Sassun-Mayo staging system, which integrates tumor deposit and lymph node counts, improves prognostic accuracy for patients with colon cancer compared with the standard American Joint ...

Mayo Clinic says tt three years, 86.3% of patients who received immunotherapy plus chemotherapy were alive and free of ...

The FDA has approved atezolizumab with chemotherapy for adjuvant treatment of stage III dMMR colon cancer after the phase III ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...

FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk ...